The success of any new drug or FDC largely depends on the rationale and justification for using it. In line with the new regulations at CDSCO, all cases of new drugs, FDCs, New Devices, Global Clinical Trials etc are discussed by the NDAC expert committee of concerned therapeutic area in the presence of the sponsor before granting approval. CliniExperts have the capabilities to represent sponsor at the NDAC meeting. We can also evaluate sponsor’s proposal and can guide them to handle their cases at the at NDAC meeting.
What a Revised Schedule M raises GMP standards in India, what has changed for manufacturers, and how large firms and MSMEs can prepare for Compliance and CDSCO inspections. Revised Schedule M is the b..
A practical comparison of CDSCO vs FDA vs EMA, explaining how each regulator’s Drug approval process differs and why one Drug needs separate approvals in India, the US and Europe. A Drug approve..
A quick guide on the Class A & B Medical Device manufacturing license — covering State FDA rules, Form MD-3/MD-5, fees, and timelines for manufacturers. Every manufacturer entering India’s..